Edwards Lifesciences logo

Edwards LifesciencesEW

NYSE

Medical Supplies

$85.65+0.15%

AI Multi-Horizon Analysis

Short-term70% confidence
Bearish

1m RSI超买后回落,MACD柱状线收窄,量能放大但价格未能突破布林上轨,短期承压。

Mid-term65% confidence
Bearish

1H与15m MACD死叉,价格位于EMA26下方,内部人持续净卖出,短线偏空。

Long-term60% confidence
Bullish

1W与1mo MACD金叉,RSI未超买,毛利率维持78%高位,长期趋势仍向上。

Overall AI View55% confidence
Neutral

多时间框架信号混杂,1H与15m偏空而1W与1mo仍偏多,内部人净卖出增加不确定性,短期方向不明。

Detailed AI Fundamental Analysis

This analysis was originally written in Chinese (China). No matching English run is cached yet — kick off a live analysis above to generate one.

业务速览

  • Edwards Lifesciences Corp(EW)为纽约证券交易所上市的普通股(CS),主要从事结构性心脏病医疗器械的研发与销售,当前股价 84.5813 美元。
  • 公司最新一季(2026-03-31)实现营收 16.486 亿美元,毛利率保持在 78.01% 的高位,显示核心产品定价能力稳定。
  • 过去四个财报周期中,经营活动产生的现金流呈现明显波动,最新季度仅录得 4380 万美元,较上年全年 15.952 亿美元大幅回落。

财务趋势

  • 营收轨迹:2025-06-30(15.322 亿)→ 2025-09-30(15.531 亿,环比 +1.36%)→ 2025-12-31 全年(60.676 亿)→ 2026-03-31(16.486 亿,环比 +6.13%),呈现温和增长后季节性回落特征。
  • 毛利率:77.52% → 77.77% → 78.01% → 78.01%,四期基本持平,显示成本控制稳定。
  • 经营利润率:26.84% → 19.77% → 20.84% → 28.97%,最新季度大幅回升 8.13 个百分点,显示费用控制或产品组合优化。
  • 自由现金流(FCF):4.653 亿 → 9.815 亿 → 13.350 亿 → -0.211 亿,最新季度由正转负,降幅超过 100%,主要因经营现金流骤降及资本开支维持在 0.649 亿。
  • 资产负债表:总资产 133.212 亿(较四期前 134.887 亿下降 1.24%),股东权益 103.275 亿(较四期前 105.453 亿下降 2.06%),长期债务维持在 5.985 亿不变,Debt/Equity 稳定在 0.06 的低位。

财务健康

  • 最新季度流动比率 4.42,高于前三期均值,短期偿债能力充裕;营运资本 48.197 亿,较上季 49.252 亿小幅回落,但仍处于高位。
  • 现金及等价物降至 24.455 亿,较四期前 32.728 亿减少 25.3%,主要受融资活动净流出 4.512 亿及投资活动净流出 0.928 亿影响。
  • 留存收益持续增加至 146.212 亿,较四期前增长 5.51%,显示盈利积累仍在进行,但现金生成能力出现阶段性减弱需持续关注。

内部人活动

  • 2026-04-23 至 2026-07-22 期间,内部人 sentiment 为 Neutral(-10),净卖出 869.70 万美元。
  • 卖出交易 19 笔、金额 883.20 万美元,买入交易 9 笔、金额仅 13.50 万美元,净流出显著。
  • 近期交易示例:Lippis Daniel J 于 2026-07-10 以 72.68 美元买入后随即以 91.70 美元卖出,获利了结;Bruls Annette 于 2026-07-11 以 92.21 美元卖出 109 股。

多周期技术面

  • 1m:RSI14=75.61(超买),MACD 柱状线 0.0428 > signal 0.0377,价格站稳 EMA50,量能放大,短线偏多。
  • 15m:RSI14=40.15(中性偏弱),MACD 柱状线 0.0613 < signal 0.068,价格位于布林带中轨下方,量能低于 20 期均值,短线承压。
  • 1H:RSI14=45.40,MACD=-0.5324 < signal=-0.69,价格回落至 EMA26 下方,ATR=0.7071,波动放大,偏空。
  • 1D:RSI14=27.84(超卖),MACD=-0.6148 < signal=0.5132,价格位于布林带下轨附近,成交量 168 万股低于 20 日均量,底部信号显现但未确认反转。
  • 1W:RSI14=55.24,MACD=1.8735 > signal=1.6912,价格站上 EMA26,布林带开口扩大,偏多。
  • 1mo:RSI14=56.53,MACD=1.9262 > signal=0.9583,价格位于布林带中轨上方,长期趋势仍向上。

多空论点

  • 短期(数小时至数日):1H 与 15m 均显示 MACD 死叉、价格回落,叠加内部人净卖出,存在进一步回调压力,倾向 SHORT。
  • 长期(数周至数月):1W 与 1mo MACD 金叉、RSI 未超买,且公司毛利率与经营利润率维持高位,基本面支撑仍在,倾向 LONG。
  • 平衡观点:超卖的 1D RSI 可能提供短期反弹,但需等待成交量配合与内部人卖压缓解,否则反弹易夭折。

关键价位与触发条件

  • 阻力位:布林带上轨 86.10(1H)、90.11(1D)、93.16(1W);突破 86.10 并站稳 4 小时以上可视为多头确认。
  • 支撑位:布林带下轨 83.09(1H)、83.41(1D)、75.98(1W);失守 83.09 配合放量可能加速下探 80 附近。
  • 触发条件:LONG 需 1H 收盘站上 86.10 且 1D RSI 脱离 30 以下;SHORT 需 1H 跌破 83.09 并伴随量能放大至 20 期均值 1.5 倍以上。

Financials

From SEC EDGAR · Period 2026-03-31 · Source form 10-Q

Income Statement · last 4 periods

 
2026-03-31
10-Q
2025-12-31
10-K
2025-09-30
10-Q
2025-06-30
10-Q
Revenue$1.65B$6.07B$1.55B$1.53B
Gross Profit$1.29B$4.73B$1.21B$1.19B
Operating Income$477.60M$1.26B$307.10M$411.20M
Net Income$380.70M$1.07B$291.10M$333.20M
EPS (Diluted)$0.66$1.83$0.50$0.56
Gross Margin78.01%78.01%77.77%77.52%
Operating Margin28.97%20.84%19.77%26.84%
Net Margin23.09%17.69%18.74%21.75%

Balance Sheet · last 4 periods

 
2026-03-31
10-Q
2025-12-31
10-Q
2025-09-30
10-Q
2025-06-30
10-Q
Total Assets$13.32B$13.70B$13.27B$13.49B
Total Liabilities$2.99B$3.36B$3.07B$2.88B
Shareholders' Equity$10.33B$10.34B$10.21B$10.55B
Cash & Equivalents$2.45B$2.94B$2.69B$3.27B
Long-term Debt$598.50M$598.30M$598.20M$598.00M
Current Ratio4.423.724.004.68
Debt / Equity0.060.060.060.06

Cash Flow · last 4 periods

 
2026-03-31
10-Q
2025-12-31
10-K
2025-09-30
10-Q
2025-06-30
10-Q
Cash from Operations$43.80M$1.60B$1.14B$570.60M
Cash from Investing-$92.80M-$712.90M-$514.60M-$86.80M
Cash from Financing-$451.20M-$956.80M-$945.40M-$205.30M
Capital Expenditures$64.90M$260.20M$162.80M$105.30M
Free Cash Flow-$21.10M$1.33B$981.50M$465.30M

Income Statement

Revenue
$1.65B
Gross Profit
$1.29B
Operating Income
$477.60M
Net Income
$380.70M
EPS (Basic)
$0.66
EPS (Diluted)
$0.66

Balance Sheet

Total Assets
$13.32B
Total Liabilities
$2.99B
Shareholders' Equity
$10.33B
Cash & Equivalents
$2.45B
Long-term Debt
$598.50M
Shares Outstanding
575.80M

Cash Flow

Cash from Operations
$43.80M
Cash from Investing
-$92.80M
Cash from Financing
-$451.20M
Capital Expenditures
$64.90M
Free Cash Flow
-$21.10M

Key Ratios

Gross Margin
78.01%
Operating Margin
28.97%
Net Margin
23.09%
Current Ratio
4.42
Debt / Equity
0.06
Free Cash Flow
-$21.10M

Insider Activity

5 insider filings (2026-06-22 to 2026-07-22) — sourced directly from SEC Forms 4/5

Buys
$90.0K · 6
Sells
$159.3K · 6
Net
-$69.3K
Filings Parsed
5
Trade DateInsiderActionSharesPriceValue
2026-07-11Bruls AnnetteSell109$92.21$10.1K
2026-07-10Lippis Daniel J.Buy619$72.68$45.0K
2026-07-10Lippis Daniel J.Sell619$91.70$56.8K
2026-07-10Lippis Daniel J.Sell619$0.00$0.00
2026-07-09Mistras TheodoraBuy87,595$0.00$0.00
2026-07-09Mistras TheodoraBuy12,325$0.00$0.00
2026-07-09Mistras TheodoraBuy61,800$0.00$0.00
2026-07-09Mistras TheodoraBuy12,325$0.00$0.00

Key Stats

$45.96BMarket cap
$87.8952-week high
$72.3052-week low
5,136,189Avg volume (30d)

16,000 employees576.54M shares outstandinglisted 2000-04-03

Next earnings ~May 5, 2026

About Edwards Lifesciences

Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.

Latest News

Showing market-wide stock news

Related Stocksin Medical Supplies

Ready to see the live AI view on EW?

Launch a real-time multi-agent room — Claude, GPT, Gemini, DeepSeek, Grok, and Qwen analyzing EW side-by-side with live signals.